Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma
Maria Schwaederlé(AstraZeneca (Japan)), Razelle Kurzrock(Medical College of Wisconsin), Lyudmila Bazhenova(Memorial Sloan Kettering Cancer Center), Kimberly C. Banks(Guardant (United States)), AmirAli Talasaz(Guardant (United States)), Megumi Ikeda(Center for Personalized Cancer Treatment), Richard B. Lanman(C.T. de Wit Graduate School for Production Ecology and Resource Conservation), Sandip Pravin Patel(University of California San Diego), Hatim Husain(University of California, San Diego)
Cited by 147
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Direct detection of early-stage cancers using circulating tumor DNA
|Science Translational Medicine|2017|1.1k